Context: Harbour Antibodies, a Dutch subsidiary of China’s Harbour BioMed, develops so-called Harbour Mice to create antibodies for the research, development, and production of biologic drugs. In December 23, 2021, Harbour Antibodies, Erasmus University Medical Center Rotterdam, and Dr. Roger Kingdon Craig sued Teneobio (a clinical-stage biotech company bought by Amgen in late 2021: October 19, 2021 Amgen press release) in the United States District Court for the District of Delaware over the alleged infringement of four patents: U.S. Patent No. 9,346,877 (“Binding molecules”), U.S. Patent No. 9,353,179 (“Binding molecules”), U.S. Patent No. 10,906,970 (“Methods of making heavy chain only antibodies using transgenic animals”), and U.S. Patent No. 10,993,420 (“Production of heavy chain only antibodies in transgenic mammals”). The suit asserted that Teneobio’s UniRat system for genetically engineering rats infringed its ​technology. A jury trial was held last week, between June 8 and June 12, 2026, overseen by Judge Maryellen Noreika.
To Read The Full Story
Continue reading your article with a Membership
Counsel
Harbour Antibodies and Erasmus University Medical Center Rotterdam are being represented by Connolly Gallagher’s Alan Richard Silverstein, Potter Anderson & Corroon’s David Ellis Moore, Bindu Ann George Palapura, and Malisa Dang, as well as a team at Desmarais: Adam Steinmetz, Brian D. Matty, John M. Desmarais, Jordan N. Malz, Jun H. Tong, Karl Mullen, Kyle G. Petrie, Maria Tartakovsky, Michael E. Furrow, Pascale S. Boonstra, Rebecca A. Lindhorst, Tamir Packin, Thomas Romanchek, and Timothy T. Golian.
Co-plaintiff Dr. Roger Kingdon Craig is being represented by Ashby & Geddes’s Andrew Colin Mayo, as well as Naini P.C.’s Amir Naini and Nutter’s Kathleen M. Williams.
Meanwhile, Teneobio (Amgen) is being represented by Morris, Nichols, Arsht & Tunnell’s Jeremy A. Tigan, Cameron Paul Clark, and Megan Elizabeth Dellinger, as well as Groombridge, Wu, Baughman & Stone’s Chih-Wei Wu, Chris Keller, Eliza P. Strong, Eric Alan Stone, Jennifer R. Deneault, Jessica Zhao, Megan F. Raymond, Nicholas P. Groombridge, Peter H. Sandel, Philip S. May, Rebecca E. Fett, and Stephen Maniscalco. The team also includes in-house counsel at Amgen: Gwen Hochman Stewart, J. Drew Diamond, Joseph E. Lasher, Steven Tang, and Wendy A. Whiteford.